Oruka Therapeutics, Inc. (NASDAQ: ORKA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $40.00 price target on the stock.
Oruka Therapeutics to Present at Piper Sandler’s 36th Annual Healthcare Conference
Oruka Therapeutics GAAP EPS of -$1.46 misses by $1.08 [Seeking Alpha]
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update